- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04163978
Nitric Oxide Releasing Sinus Irrigation (NOSi) to Treat Recalcitrant Chronic Rhinosinusitis (RCRS)
June 28, 2022 updated by: Sanotize Research and Development corp.
Phase 2 Trial to Evaluate Safety & Efficacy of Topical Nitric Oxide Releasing Sinus Irrigation (NOSi) as Compared to Budesonide-Saline (Control) in the Management of Biofilm-Associated Recalcitrant Chronic Rhinosinusitis (RCRS)
This a single center, randomized controlled trial to evaluate safety & efficacy of topical nitric oxide releasing sinus irrigation (NOSi) as compared to budesonide-Saline (Control) in the management of biofilm-associated recalcitrant chronic rhinosinusitis (RCRS).
It is hypothesized that a daily treatment of NOSi over a 6-week period will be safe and effective at reducing clinical symptoms associated with RCRS.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, single center, Phase 2, double-blinded, randomized, controlled, parallel group trial study.
Up to fifty-four (54) participants will be enrolled (based on power analysis based on outcomes from a previous dose-tolerance study.
Screening data will be reviewed to determine participant eligibility.
Participants who meet all inclusion criteria and none of the exclusion criteria will be entered into the study and randomized in to the Investigational Medicinal Product (IMP) or Non Investigational Medicinal Product (NIMP) at a 2:1 ratio (NOSi:Budesonide).
Each participant will be managed as an outpatient for the 42 days of the study.
Participants will be administered NOSi or budesonide in saline by self-administration, at home, as a sinus irrigation to their nasopharynx and sinuses once a day.
Participants will be asked to return to the clinic for evaluations on Day 21(±2), Day 43(±2) and Day 63 (±2) following the start of study interventions.
Study Type
Interventional
Enrollment (Actual)
56
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 1Y6
- St. Paul's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
17 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent must be obtained from the participant prior to entering the study.
- Must be ≥ 19 years of age unless local laws dictate otherwise
- English speaking
- Willing and able to return to the study site for protocol required visits.
- Documented diagnosis of chronic sinusitis with biofilm after a treatment of at least 3 months of a combination of well executed sinus surgery, regular irrigation with topical steroids or a mucosal atomization device and surfactants and at least one course of culture directed oral antibiotics
- Persistent or worsening symptoms within 30 days of wash-in with budesonide. Specifically, documented by two SNOT-22 scores greater than or equal to 20 indicating stable (within 9 points) or worsening symptoms. SNOT-22 evaluations must be at least 7 days and no more than 30 days apart. Second SNOT-22 must be used as baseline.
- Participant has been on a stable course of only Pulmicort and saline irrigation for a minimum of 30 days prior to randomization
- Must be willing to use an adequate and documented form of contraception (or abstinence) from the time of the first dose with the IMP until after the last dose of IMP
Exclusion Criteria:
- Presence of prior history of sinonasal tumors
- Isolated sphenoid sinusitis or other sinus cavities that are not accessible to a nasal/sinus rinse as done by the patient in the head forward position
- Autoimmune diseases affecting the upper airway eg Systemic lupus erythematosus, Sjögren's syndrome, systemic sclerosis etc
- Immuno-compromised patients, and patients with impairment in mucociliary function (e.g., cystic fibrosis, Kartagener syndrome)
- Severe underlying disease with anticipated survival less than 6 months
- Females who are pregnant, breastfeeding, or plan to become pregnant during the course of the study up to 1 weeks after the last dose/study visit
- Has used any investigational drug(s) within 30 days preceding randomization visit (Day 1);
- Suffers from a condition, which, in the opinion of the medical investigator, would compromise their safety and / or their adherence to the study protocol
- Systemic antibiotics, corticosteroids or antifungals within 30 days of randomization
- Intranasal or irrigation with antibiotics, antifungals or antiseptics or any other sinusitis treatment other than Pulmicort within 30 days of randomization
- Has a family member living in the same household, also enrolled or planning to enroll in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nitric oxide releasing solution (NOSi)
DailyTopical sinus irrigation delivery of 240mL NOSi
|
in situ 240mL nitric oxide releasing sinus irrigation solution
Other Names:
|
Active Comparator: Budesonide -saline
Daily Topical sinus irrigation delivery of 240 mL of 1 mg Budesonide-saline
|
Saline based sinus irrigation 1mg Budesinide solution
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the efficacy of NOSi compared to Budesonide on disease specific quality of life in participants with biofilm-associated recalcitrant chronic rhinosinusitis (RCRS) as measured by the Sino-Nasal Outcome Test (SNOT-22)
Time Frame: 42 days
|
Proportion of participants experiencing a 9-point reduction in Sino-Nasal Outcome test (SNOT-22) score (0-5 scale of 22 parameters with a total maxmimum score of 110 and an increased value representing worsening of condition)
|
42 days
|
To assess the safety of NOSi compared to Budesonide on disease specific quality of life in participants with biofilm-associated recalcitrant chronic rhinosinusitis
Time Frame: 63 days
|
Severity and frequency of adverse events as well as clinically significant Changes in laboratory findings, vital signs, histology, olfaction, and methemoglobin levels.
|
63 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the efficacy of NOSi compared to Budesonide on the reduction of Modified Lund-Kennedy Scores (MLK)
Time Frame: Days 21, 42, 63
|
Mean change in MLK score as compared to control (Scale of 0-2 for 6 locations on each side (maximum total score 24); increase represents worsening
|
Days 21, 42, 63
|
To evaluate the efficacy of NOSi compared to Budesonide on quality of life improvements (EQ-5D-5L);
Time Frame: Days 21, 42, 63
|
Mean change in EQ-5D-5L index score as compared to control (Scale 0-100; increase indicates worsening)
|
Days 21, 42, 63
|
To evaluate the efficacy of NOSi compared to Budesonide on the density of pathogens
Time Frame: Days 21, 42, 63
|
Mean change in pathogen density compared to control; (log10 cfu/g)
|
Days 21, 42, 63
|
To evaluate the efficacy of NOSi compared to Budesonide on cilia functionality
Time Frame: Days 43 & 63
|
Proportion of participants with functional cilia which is known to be denuded by biofilm as determined by the saccharin test compared to control
|
Days 43 & 63
|
To evaluate the efficacy of NOSi compared to Budesonide on biofilm elimination
Time Frame: Days 43 & 63
|
Proportion of participants with biofilm elimination compared to control
|
Days 43 & 63
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Amin Javer, MD, St. Paul's Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 27, 2019
Primary Completion (Actual)
May 3, 2022
Study Completion (Actual)
May 3, 2022
Study Registration Dates
First Submitted
October 31, 2019
First Submitted That Met QC Criteria
November 12, 2019
First Posted (Actual)
November 15, 2019
Study Record Updates
Last Update Posted (Actual)
June 30, 2022
Last Update Submitted That Met QC Criteria
June 28, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Otorhinolaryngologic Diseases
- Paranasal Sinus Diseases
- Nose Diseases
- Sinusitis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protective Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Antioxidants
- Free Radical Scavengers
- Endothelium-Dependent Relaxing Factors
- Gasotransmitters
- Budesonide
- Nitric Oxide
Other Study ID Numbers
- NOSi-CTP-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Sinusitis
-
Loma Linda UniversityWithdrawnChronic Sinus Disease | Chronic Sinusitis, Ethmoidal | Chronic Sinusitis, Sphenoidal | Chronic Sinusitis - Maxillary Bilateral | Chronic Sinusitis - Frontoethmoidal
-
LifeBridge HealthUnknownChronic Sinusitis | Nasal Polyps | Chronic Sinusitis, Ethmoidal | Chronic Sinusitis, Sphenoidal | Chronic Sinusitis - Frontoethmoidal | Chronic Sinusitis - Ethmoidal, Posterior | Chronic Sinusitis - Ethmoidal Anterior | Nasal Polyp - PosteriorUnited States
-
Kaiser PermanenteWithdrawnChronic Sinusitis | Chronic Sinus Infection | Chronic Sinusitis - Ethmoidal, Posterior | Chronic Sinus CongestionUnited States
-
Collin County Ear Nose & ThroatIntersect ENTCompletedChronic Sinusitis, EthmoidalUnited States
-
Tampere University HospitalRecruitingMaxillary Sinusitis | Eustachian Tube Dysfunction | Sinusitis, Chronic | Sinusitis RecurrentFinland
-
STS MedicalNot yet recruitingChronic Sinusitis, Ethmoidal
-
Centre Hospitalier Intercommunal CreteilRecruitingSinusitis, Chronic | Sinus Infection ChronicFrance
-
Lyra TherapeuticsCompletedChronic Sinusitis | Chronic Rhinosinusitis (Diagnosis)United States, Australia
-
Optinose US Inc.CompletedChronic Sinusitis With or Without Nasal PolypsUnited States
-
Lyra TherapeuticsCompletedChronic Sinusitis | Chronic Rhinosinusitis (Diagnosis)Poland, Australia, New Zealand, Austria, Czechia
Clinical Trials on Nitric Oxide
-
Beyond Air Inc.Recruiting
-
Tomsk National Research Medical Center of the Russian...Siberian State Medical UniversityCompletedCoronavirus Infection | Pneumonia, Viral | HypoxemiaRussian Federation
-
Instituto Nacional de Ciencias Medicas y Nutricion...Completed
-
BellerophonCompletedChronic Obstructive Pulmonary Disease | Idiopathic Pulmonary Fibrosis | Pulmonary HypertensionBelgium
-
MallinckrodtCompletedIdiopathic Pulmonary Arterial Hypertension | CardiomyopathyUnited Kingdom, United States, France, Spain, Netherlands
-
William Beaumont HospitalsTerminatedClostridium Difficile ColitisUnited States
-
National Institute of Neurological Disorders and...CompletedHealthy | Fabry Disease | Cerebrovascular AccidentUnited States
-
Origin Inc.UnknownDiabetic Foot UlcerUnited States
-
National Institute of General Medical Sciences...Completed
-
Sanotize Research and Development corp.Withdrawn